Malaria vaccine ingredients
There are currently no commercially available vaccines for malaria. However, several promising candidates are in development, each with its own unique ingredients:
1. RTS,S/AS01 (Mosquirix): This is the only malaria vaccine that has received regulatory approval. It is a recombinant protein vaccine that targets the circumsporozoite protein (CSP) on the surface of Plasmodium falciparum sporozoites, the stage of the parasite transmitted by mosquitoes. The vaccineand#39;s ingredients include:
2. PfSPZ Vaccine: This is a candidate vaccine developed by Sanaria using radiation-attenuated sporozoites. These are live, weakened sporozoites that can stimulate the immune system to produce a protective response against malaria. The vaccineand#39;s ingredients include:
3. R21/Matrix-M: This is a candidate vaccine that uses a combination of a viral vector and a protein adjuvant. The viral vector delivers genetic material that instructs the bodyand#39;s cells to produce the CSP protein. The protein adjuvant helps to boost the immune response to the vaccine. The vaccineand#39;s ingredients include:
4. ME-TRAP: This is a candidate vaccine that targets the Merozoite TRAP protein, which is essential for the parasiteand#39;s invasion of red blood cells. The vaccineand#39;s ingredients include:
It is important to note that these are just a few examples of the many different malaria vaccine candidates currently in development. Each vaccine has its own unique ingredients and formulation, and the specific ingredients may change as the vaccines continue to be developed and tested.
Please note that this information is for educational purposes only and should not be construed as medical advice. Please consult with a healthcare professional for more information about malaria vaccines.
Sources: